Guys check this on out - just had a spike on good news.
ChromoCure, Inc. Announces Development of New Generation of High-Speed Chromosomal Scanners for Cancer Detection Date : 08/31/2009 * 2:27PM Source : MarketWire Stock : ChromoCure, Inc. (KKUR) Quote : 0.0016 0.0007 (77.78%) * 8:06AM
ChromoCure, Inc. Announces Development of New Generation of High-Speed Chromosomal Scanners for Cancer Detection
RENO, NV -- (Marketwire) -- 08/31/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) released today its development plan for its next generation of chromosomal scanners. The new system has been given the name "CS300" as the next iteration of its current CS200 Chromosomal Scanner design.
The new CS300 will retain all of the features of CS200 with these important additions:
-- On-Slide direct application of DNA-probes using robotic micro-applicator
-- User-selectable chromosome probe types -- one probe or multiple simultaneous probes
-- Full integration of de-paraffinization and cellular disaggregation of tissue samples for non-cytology originated diagnostics
The CS300's design parameters introduce significant throughput improvements allowing the CS300 to process hundreds of patient scans per day, per machine. The company is not aware of any similar automated high-speed chromosomal scanner in the marketplace.
The company has executed a joint research and development agreement with one of its equipment partners to complete the CS300 in preparation for a nationwide marketing plan.
The Company is completing its consolidated GAAP financials statements for the year 2007 through 2009. These financials are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines and will be timely published as part of the Company's ongoing disclosure practices.
The Company anticipates updating stockholders on the following items:
-- Announcement of joint research and development agreement
-- Initial scanner installations with diagnostic labs
-- Elimination of significant long-term liabilities and removal from the Balance Sheet
-- Acquisition of intellectual property, technology, and subsequent patent filings
-- Additional appointment to the Company's Advisory and Business Development Boards
-- Acquisition of profitable pathology labs to expand the company's operations
-- Research and Development agreements with industry partners
-- Regular updates and commentary on the Company's technology
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations:
Contact:
ChromoCure, Inc.
info*chromocure.com
Tel 1.775.636.6548
Posted by jdizz on :
man i was about to post that lol.. i got in and got out real quick..
Posted by jdizz on :
its still running thought.. prob gunna have another good run
Posted by Charbel on :
do you recommend buying short now and wait till morning or might go up still?
Posted by jdizz on :
I wouldnt get in it anymore b.c its the end of the day and people want their mony and dont want to hold overnight. just my opionion..
Posted by Charbel on :
sounds good. I am going to keep an eye on it, chart looks good for a short right after a spike usually. But well see.
Posted by beerlady on :
with this news out today, i think it will make another run in the morn. Im in :-)
Posted by jdizz on :
looks like it will have another run today possible! i hope you do good on this one! i kinda am pissed b.c i pulld out and made only 100bucks.. o well more than what i started with right.
Posted by jdizz on :
on etrade you can see all the news when it first comes out. im sure its like that on every brokerage account, but i just found that out.. i saw this at .0011 but didnt but in until .002 lol.
Posted by Hot-Pepper on :
I am in at .0029 maybe by tomorrow it will take a much deserved rise. imo
Posted by jdizz on :
awesome close
Posted by beerlady on :
hey hottie (pepper) i'm in too...I got in later than I wanted (.0028), but, I'm in, so lets hope this one does well in the am. If so, we will owe brokes a big thank you. She always has some darn good picks too! Im thinking this should run for a day or two with that kind of news. GLTA
Posted by Love the Market on :
Is this still a good one to buy? Was there any bad news this morning?
Posted by Charbel on :
was wondering the same thing too? any suggestions?
Posted by Love the Market on :
I'm checking the wire for bad news... I'll be back
Posted by Love the Market on :
I can't find anything.
Posted by jdizz on :
migh be a good buy.. looks like .0023 is the resisting point.. be carfull though bc there were massive sell offs this morning. volume already liek 32mil
Posted by beerlady on :
I have not seen any bad news, or new news either. Im in and hoping for a BIG ONE!!
Posted by Hot-Pepper on :
Hello Beerlady, I am still in and already It's down this morning. There was a big sell off this morning and drove the stock down to where we have seen so far. It opened at 0.0024 after closing at 0.0034 previously. It's not running as we thought with the news that came out late yesterday. I have search around and have not seen any bad news. Maybe it is affected by the market, which is generally down today. Unless it's going to jump right back up towards the end of the trading hour as it did yesterday, except that there is no news .....maybe it's an opportunity to pick up more, then sit and wait.....I really do not know if I should sit and wait on this one. I got in at 0.0029 and now the bid is 0.0018 Yaiks... and the volume is 83,140,392
Posted by Love the Market on :
Let's hope tomorrow's better that today on this one!
Posted by Love the Market on :
KKUR has exploded to a high of 0.0033 from an opening of 0.0013.
Posted by Love the Market on :
Anybody here? It's FLYING - was up to .0033 on NEWS!
Posted by jdizz on :
man i want to get in, slown down tho? anythoughts
Posted by Hot-Pepper on :
ChromoCure, Inc. Announces Technology and Intellectual Property Assets Acquisition Adding $1,500,000 to Assets and EquityFont size: A | A | A11:58 AM ET 9/3/09 | Market Wire ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed a Technology Purchase and Transfer Agreement for $1,500,000, payable in Preferred Stock, wherein the Company receives full title and transfer of all rights, trademarks, intellectual property, protocols, patent disclosures, chromosomal scanner equipment, all proprietary analysis algorithms, mathematical analysis procedures, prior testing data with cancer clinics, cell preparation procedures, and all new hardware designs currently in development related to cancer detection and chromosomal scanning, enumeration, and analysis.
The transaction structure was specifically designed to avoid incurring long-term liabilities in the form of shareholder equity-reducing debt. Instead, the acquisition adds assets and equity and builds shareholder equity.
As previously disclosed, the transition of the company to its new business plan and operations is an essential component of the company's 2009 plan for operations. The Company executed this portion of it plan of operations as previously planned to be immediately subsequent to completion of financial disclosures and filings.
The company recently completed its disclosures and financials as part of this transition plan and succeeded in the removal of the "Caveat Emptor" status associated with the company's prior operations.
The remainder of the Company's plan of operations for 2009 will continue to be executed and investors updated accordingly.
Updates will be timely published on the following:
View data-- Announcement of joint research and development agreement. -- Initial scanner installations with diagnostic labs. -- Elimination of significant long-term liabilities and removal from the Balance Sheet. -- Additional appointments to the Company's Advisory Boards. -- Acquisition of profitable labs to expand the company's operations. -- Release of technology and industry White Papers.
-- Announcement of joint research and development agreement. -- Initial scanner installations with diagnostic labs. -- Elimination of significant long-term liabilities and removal from the Balance Sheet. -- Additional appointments to the Company's Advisory Boards. -- Acquisition of profitable labs to expand the company's operations. -- Release of technology and industry White Papers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations: Contact: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
SOURCE: ChromoCure, Inc.
mailto:info*chromocure.com
Posted by Love the Market on :
jdizz - I hope you didn't get in anywhere over .0021 - .0022.....99% of the time if you chase these suckers you lose big time.
Hot-Pepper, I've been out today - but I hope you made bank on this and BWNR. Crap - I wish I could have gotten out of this and that one today - with a profit no less, albeit not much on BWNR - in at .0007 a few weeks ago. In here 2 days ago at .0022
Posted by Hot-Pepper on :
Love the Market, Yes, I made money on BWNR. I am hoping for another 0.0003 to get in. KKUR was kinda frustrating for me. I should not have gone out, but my stop loss triggered whenit was dropping from the 0.0029 price that I bought. If I had stayed in, I would have recovered my losses on KKUR. I am not bitter since BWNR came through very well for me today.
Posted by Love the Market on :
Hot - imo you can't use stops on pennies. In fact you can't use stops on the big boards either - again jmho. Look at BONU the past few days - Down .61 - UP .45 4 minutes later! And you would have gotten killed in C and BAC ($8.00+ swing the same day) over the past few months. or KKUR today...
Posted by beerlady on :
New news out today guys...maybe she'll finally make a big run?
ChromoCure, Inc. Announces Co-Development Agreement for New CS300Scanner Series in Preparation for Nationwide Distribution
Sep 4, 2009 12:22:58 (ET)
RENO, NV, Sep 04, 2009 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed a Technology Co-Development Agreement with its primary cell preparation and application technology supplier. The co-development agreement calls for the joint-development of a fully integrated chromosomal scanner system for nation-wide distribution to pathology and related cancer detection labs.
The agreement calls for the technical collaboration and partnership between the companies and joint technical research and development efforts to complete a fully automated hybridization system allowing for a complete 'end-to-end' chromosomal scanning solution. The company has named the system "CS300" and represents a significant advancement in automating every aspect of the preparation and scanning cycles of the CS200's current automation capabilities and design.
The feature set of the new system is anticipated to include:
-- Ability to perform a full 23-pair chromosomal cross-sectioning for every cell within a sample -- Integration of solid tissue disaggregation inputs and automation -- Integration for inputs derived from de-paraffinization protocols for histo-pathology research and patient tissue archive recovery and assay -- Parallel DNA-probe insertions across hybridizing channels for rapid scans across multiple chromosomes -- Ability to integrate solid tumor incubation equipment for therapeutic and cancer cure protocols testing.
The remainder of the Company's plan of operations for 2009 will continue to be executed and investors updated accordingly.
Updates will be timely published on the following:
-- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Additional appointments to the Company's Advisory Boards -- Acquisition of profitable labs to expand the company's operations -- Release of technology and industry White Papers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Contact: Investor Relations: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
Posted by Hot-Pepper on :
I got in again at a lower price to re-coop my $$$$.
Posted by Hot-Pepper on :
ChromoCure, Inc. Announces Elimination of $800,000 of Debt WithCyberhand Asset Sale
Sep 9, 2009 09:30:10 (ET)
VANCOUVER, BC, Sep 09, 2009 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed an Asset Purchase Agreement with certain secured creditors owning $800,000 of company debt. The debt is secured by all of the assets of the prior "Cyberhand" operations. The Company and the creditors have agreed to exchange these assets for complete elimination of the debt.
As previously announced, it is the intention of the creditors to establish new operations with the Cyberhand assets and distribute stock in the new company, pro rata, to all prior stockholders of Cyberhand. ChromoCure has agreed to supply the new company with all shareholder information for the planned stock distribution.
The transaction structure was specifically designed to eliminate long-term liabilities. The elimination of this long-term liability releases the company from its secured debt obligation and improves shareholder equity.
Elimination of this Note removes substantially all of the company's long-term liabilities and leaves the company comparatively debt-free.
Updates will be timely published on the following:
-- Announcement of joint research and development agreement -- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Additional appointments to the Company's Advisory Boards -- Acquisition of profitable labs to expand the company's operations -- Release of technology and industry White Papers
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology is superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations: Contact: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
SOURCE: ChromoCure, Inc.
mailto:info*chromocure.com
Posted by Hot-Pepper on :
ANOTHER CHANCE TO GET IN !!!
Posted by Hot-Pepper on :
I GUESS IT'S GOODNEWS TO RETIRE A DEBT OF SUCH MAGNITUDE !!
Posted by beerlady on :
im still in, and hopin for a big run... Posted by Hot-Pepper on :
You and me both.
Posted by western acres on :
I'm still trying to learn how to tell what the resistance # are. Does someone have a # in mind for this one.
Posted by Love the Market on :
Hope this junk gets to .003 FAST and I'm out! I'm bleeding badly today all over- except GERS
Posted by Hot-Pepper on :
Hello Love the Market. You are not alone. I am bleeding all over today. I guess I'll do nothing today except watch them. I will lose no money unless I sell anything at a lower route....if you know what I mean.
Posted by Love the Market on :
Hey bud - I can't believe what's happened in the past week with this, SALN, OMHI, OPGX , BWNR, IDOI and all my other losers! It's like: "Let's get Steve week"! Oh well - looks like I need two or three more ATNO comebacks to get out even or with a little $$.
What do you think the KKUR news will do - if anything? So far it's only .0017 - I had my sell in for .0034 ALMOST got it last week - oh well.
Good Luck!
Posted by Hot-Pepper on :
KKUR will get to your target imo. A great news release of progress or something will land us there imo.
Do nothing with OPGX, I saw a very heavy volume yesterday...(Accummulation), but there was no movement. It will fly shortly to a higher level. imo
Posted by Hot-Pepper on :
I saw another big volume today on OPGX.
Posted by Charbel on :
I am also stuck with BWNR can only wait i guess ??
Posted by Love the Market on :
Hey Gang!
At least we're here to play the game - we must thank God for that! For me - this is my desktop casino - WITHOUT leaving home! (Takes a little bit longer to lose too, compared to Black-Jack! And sometimes we get lucky and hit a grand slam... (NOT too Often though)!
Good Luck to us all. Steve
Posted by Love the Market on :
NEWS !!! Here it is:
ChromoCure, Inc. Launches Nationwide Diagnostic Lab Partnership Program
RENO, NV -- (Marketwire) -- 11/03/09 -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced its partnership program for cancer diagnostic laboratories and research centers.
Industry pathologists and cancer diagnostic research centers may request the company's partnership package and materials at:
Pathology labs will receive ChromoCure's CS200 Chromosomal Scanner installed on their premises without cost. ChromoCure will provide training, material, and marketing guidance. Established insurance codes exist for ease of billing and collections. The ChromoCure CS200 can deliver immediate revenue to pathologists.
Cancer research centers may purchase the company's equipment or use one of the company's network pathology labs to perform chromosomal scans.
Preferred pricing will be extended to all cancer research partners.
Purchasers of the CS200 chromosomal scanner will receive a favorable upgrade price to the CS300 series when released.
The company has established this special program to expand it network of pathology labs as well as promote its science and technology with cancer research centers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations:
Contact:
ChromoCure, Inc.
info@chromocure.com
Tel 1.775.636.6548
Posted by IWISHIHAD on :
Quote Love The Market:
"At least we're here to play the game - we must thank God for that! For me - this is my desktop casino - WITHOUT leaving home! (Takes a little bit longer to lose too, compared to Black-Jack! And sometimes we get lucky and hit a grand slam... (NOT too Often though)!"
_________________________________________________
I like that one!
But there(casino) you can kick the table or video poker machine and usually the worst you get is to be thrown out.
If you do that to your computor while playing the pennies, we have to pay to replace the computer and then cannot get a new one in time to catch that big bounce in our stocks.
Posted by Love the Market on :
LOL - Good one!
On this one..... I wish I HADN'T !! Stuck at .0022
News looked good - we're too diluted to fly.... Just like GERS. Crap.
I wonder how much those scanners cost??
Posted by Love the Market on :
I sure hope this gaps up or runs a little - I'll sell near or right after just to get out - Too diluted to move up to even .002 imho.
They call THIS News??? I think they did the same crap a few montha ago.....
Looking For Shareholder Opinions On ChromoCure's Latest News Looking For Shareholder Opinions On ChromoCure's Latest News Nov. 4, 2009 (M2 Communications Ltd.) --
www.PinnacleDigest.com is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from ChromoCure, Inc. (PINKSHEETS: KKUR) announcing its partnership program for cancer diagnostic laboratories and research centers, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all ChromoCure shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Find out if ChromoCure makes it as a Pinnacle Featured Company,
Chat with other shareholders invested in ChromoCure,
Explain to our investor community what differentiates this company,
Connect with investors and professionals in the equity markets,
Meet the thousands of investors who have already become members of the Pinnacle community.
PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.
PinnacleDigest.com has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated PinnacleDigest.com in any form to disseminate this release.
This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.
All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.
(Comments on this story may be sent to tww.feedback@m2.com)
Source: M2 Presswire (November 4, 2009 - 4:47 AM EST)
It's geting ready to produce. I picked up a few shares at 0.0004 today.
Posted by Hot-Pepper on :
Yesterday it moved up to 0.0006. Still time to get in and make some $$$.
Posted by Love the Market on :
I got some more to average down (In at .0022 for months)I have buy in for 1 mil at .0004 - only got 190580 filled yesterday....Order still open for almost 810,000. Good Luck.
Posted by Hot-Pepper on :
It's expected to show some strenght this month, but still waiting. I looked at HESG last week and picked up some shares at 0.0003 and today, it's high was 0.0009. and currently the asking is now at 0.0007.
Posted by western acres on :
Sorry found this late in the day.
(OTC:KKUR) on the Front Line of Cancer Detection Note to Editor, the following is an investment opinion issued by the IO News Wire
NEW YORK, NY--(Marketwire)--November 19th, 2009, ChromoCure, Inc. (OTC:KKUR-NEWS) announced recently its nationwide diagnostic lab partnership program to increase awareness of its CS200 Chromosomal Scanner, its leading cancer detection system.
ChromoCure's research demonstrates and confirms the 100% common chromosomal condition present in every form of cancer. By detecting this unique chromosomal condition the Company’s ability to detect cancer, of all types and stages, is effectively 100% accurate. ChromoCure indicates they have the ability to completely eliminate false positives and false negatives for the presence of cancer.
ChromoCure believes it CS200 Chromosomal Scanner employs the most fastest, most accurate method of detecting cancer in tissue samples by testing for cancer’s unique chromosomal imbalance. The company’s research and scientific literature both support this imbalance as most accurate predictor of cancer available in today's market. The company does not believe any cancer technology exists that uses cancer’s unique chromosomal condition combined with automated cell nucleus scanning.
ChromoCure is positioning itself in the $16.8 billion dollar cancer detection and therapy market by offering its CS200 Chromosomal Scanner and soon to be released CS300 Scanner free to all participating pathology labs along with training, materials and marketing guidance.
The Company also has certain initiatives underway to apply its understanding of cancer to both therapeutic technologies and possible cure.
Other active stocks are Biocentric Energy Holdings (OTC:BEHL) Hologic (NASDAQ:HOLX) C.R. Bard, Inc (NYSE:BCR)
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send No Faxes or emails.
Contact: Eric Jensen www.ionewswire.com 516.942.4910
Posted by Hot-Pepper on :
I am still waiting for KKUR. The above news produced about 0.0002 upward change last friday and same thing today before it finally closed at 0.0006. One of thses days we shall recoop.There will be more activities this month and early December according to rumur, so continue to keep your eyes on it.
![[Big Grin]](biggrin.gif)
![[BadOne]](graemlins/headbash.gif)
can only wait i guess ??